Skip to Main content Skip to Navigation
New interface
Journal articles

Eplerenone in patients with myocardial infarction and “mid‐range” ejection fraction: An analysis from the EPHESUS trial

Abstract : BACKGROUND: Trials using mineralocorticoid receptor antagonists (MRAs) in myocardial infraction (MI) without heart failure (HF) or systolic impairment have been underpowered to assess morbidity-mortality benefit. In EPHESUS 6632 patients were included, of whom 11% had an ejection fraction (EF) of 40% and HF or diabetes. We aim to assess the potential benefit of MRAs in MI with EF of 40%. METHODS: Cox models with interaction term for EF. The primary outcome was a composite of cardiovascular death or hospitalization for cardiovascular reasons. HYPOTHESIS: Patients with an EF of 40% benefit similarly from MRA therapy to those with an EF <40%. RESULTS: In EPHESUS, 753 patients had an EF = 40% and 5864 an EF < 40%. Patients with an EF = 40% were younger (63 vs 64 years), had lower heart rate (73 vs 75 bpm), less atrial fibrillation (10% vs 14%), previous MI (21% vs 28%), HF hospitalization (5% vs 8%), and had more often reperfusion therapy and/or revascularization (55% vs 44%). The mean EF was 40.0 ± 0.3% in those with EF = 40% vs 32.2 ± 5.9% in those with EF < 40%. The primary outcome occurred in 13.3% (10 events per 100 py) of the patients with EF = 40% vs 22.9% (19 events per 100 py) in those with EF < 40%; adjusted HR for EF = 40% vs <40% = 0.65 (0.53-0.81). Eplerenone reduced the event-rate homogenously regardless of EF (interaction p EF = 40% vs EF < 40% = 0.21). Similar findings were observed for cardiovascular and all-cause death. CONCLUSION: Eplerenone reduces hospitalizations and mortality in patients with MI and EF = 40% similarly to patients with EF < 40%. These findings suggest that MI patients with EF in the "mid-range zone" may also benefit from MRA therapy which might help clinicians in their treatment decisions. © 2019 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.
Complete list of metadata

https://hal.univ-lorraine.fr/hal-02512495
Contributor : Philippe DE CARVALHO Connect in order to contact the contributor
Submitted on : Wednesday, August 31, 2022 - 2:33:16 PM
Last modification on : Wednesday, August 31, 2022 - 3:17:49 PM

Licence


Distributed under a Creative Commons Attribution 4.0 International License

Identifiers

Citation

Joao Pedro Ferreira, Xavier Rossello, Bertram Pitt, Patrick Rossignol, Faiez Zannad. Eplerenone in patients with myocardial infarction and “mid‐range” ejection fraction: An analysis from the EPHESUS trial. Clinical Cardiology, 2019, 42 (11), pp.1106-1112. ⟨10.1002/clc.23261⟩. ⟨hal-02512495⟩

Share

Metrics

Record views

48

Files downloads

3